APN-401

N/A

Report date: 2023/09/12 11:34:28

Base Information

Drug NameAPN-401
Drug Alias NamesiRNA-transfected PBMC APN401siRNA-transfected peripheral blood mononuclear cells(Apeiron)APN-401
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionRNA interferenceE3 ubiquitin-protein ligase CBL-B expression inhibitorsCell replacements
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsBrain metastasesSolid tumoursNeoplasm Metastasis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustria
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesApeiron Biologics
China Registration ClassN/A

Develop Information

Active CompaniesApeiron BiologicsinvIOs GmbH
Inactive CompaniesWake Forest University Health Sciences
Active IndicationsSolid tumours
Inactive IndicationsBrain metastasesNeoplasm MetastasisPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A